The use of rabbit intestinal permeability as an in vitro assay in the search for orally active GPIIb/IIIa antagonists

被引:1
|
作者
Samanen, JM
Lee, CP
Smith, PL
Bondinell, WE
Calvo, RR
Jakas, DR
Newlander, KA
Parker, M
Uzinskas, I
Yellin, TO
Nichols, AJ
机构
[1] SMITHKLINE BEECHAM PHARMACEUT,DEPT DRUG DELIVERY,KING OF PRUSSIA,PA 19406
[2] SMITHKLINE BEECHAM PHARMACEUT,DEPT PHARMACOL,KING OF PRUSSIA,PA 19406
关键词
absorption; peptides; transport; permeability; pharmacophore model; GPIIb/IIIa antagonists; oral activity; bioavailability; Ussing Chamber;
D O I
10.1016/S0169-409X(96)00431-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A series of potent, high affinity GPIIb/IIIa antagonists were evaluated for intestinal permeability in vitro using rabbit intestinal strips mounted in the Ussing Chamber. In this series of compounds, structural modifications were found to impact intestinal permeability. In general, modifications that would contribute to lipophilicity (e.g. olefinic replacement for amide, phenethyl or isopropyl for methyl) did not enhance permeability. When these intestinal permeabilities were compared to mannitol, which displays similar to 20% oral bioavailability in humans (Laker et al. (1982) fur. J. Clin. Invest. 12, 485-491), it was possible then to select compounds with permeabilities comparable to mannitol for oral (intraduodenal) evaluation in conscious dogs. The influence of intestinal permeability on oral efficacy can be observed within a series of compounds with closely related structures, but is less discernable in across structural series. Intestinal permeability data can provide meaningful, reliable data that can help in analog design and in the selection of compounds for oral evaluation.
引用
收藏
页码:133 / 142
页数:10
相关论文
共 50 条
  • [11] Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists
    Rebello, SS
    Huang, J
    Faul, JD
    Lucchesi, BR
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2000, 9 (01) : 23 - 28
  • [12] Role of Extracellular Ionized Calcium in the In Vitro Assessment of GPIIb/IIIa Receptor Antagonists
    Sam S. Rebello
    Jinbao Huang
    Jessica D. Faul
    Benedict R. Lucchesi
    Journal of Thrombosis and Thrombolysis, 2000, 9 : 23 - 28
  • [13] An efficient synthesis of the orally-active GpIIb/IIIa antagonist FR184764
    Yamanaka, T
    Ohkubo, M
    Takahashi, F
    Kato, M
    TETRAHEDRON LETTERS, 2004, 45 (13) : 2843 - 2845
  • [14] Orally active peptidomimetic RGD analogs that are glycoprotein IIb/IIIa antagonists
    Wang, W
    Borchardt, RT
    Wang, B
    CURRENT MEDICINAL CHEMISTRY, 2000, 7 (04) : 437 - 453
  • [15] Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists
    Xue, CB
    Wityak, J
    Sielecki, TM
    Pinto, DJ
    Batt, DG
    Cain, GA
    Sworin, M
    Rockwell, AL
    Roderick, JJ
    Wang, SG
    Orwat, MJ
    Frietze, WE
    Bostrom, LL
    Liu, J
    Higley, CA
    Rankin, FW
    Tobin, AE
    Emmett, G
    Lalka, GK
    Sze, JY
    DiMeo, SV
    Mousa, SA
    Thoolen, MJ
    Racanelli, AL
    Hausner, EA
    Reilly, TM
    DeGrado, WF
    Wexler, RR
    Olson, RE
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (13) : 2064 - 2084
  • [16] Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs
    Ogawa, T
    Sugidachi, A
    Naganuma, H
    Asai, F
    THROMBOSIS RESEARCH, 2000, 97 (05) : 307 - 315
  • [17] SE 214857: A novel nm peptide orally active potent and selective platelet GPIIb/IIIa receptor antagonist: In vitro and in vivo pharmacology
    Feuerstein, G
    Wong, A
    Nichols, A
    Samanen, J
    Stadel, JM
    VaskoMoser, J
    Koster, P
    Valocik, R
    CIRCULATION, 1996, 94 (08) : 3007 - 3007
  • [18] Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action
    Olson, RE
    Sielecki, TM
    Wityak, J
    Pinto, DJ
    Batt, DG
    Frietze, WE
    Liu, J
    Tobin, AE
    Orwat, MJ
    Di Meo, SV
    Houghton, GC
    Lalka, GK
    Mousa, SA
    Racanelli, AL
    Hausner, EA
    Kapil, RP
    Rabel, HR
    Thoolen, MJ
    Reilly, TM
    Anderson, PS
    Wexler, RR
    JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (07) : 1178 - 1192
  • [19] Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit: Structure-activity studies leading to the discovery of RWJ-53308.
    Hoekstra, WJ
    Maryanoff, BE
    Damiano, BP
    Andrade-Gordon, P
    Cohen, JH
    Costanzo, MJ
    Costanzo, MJ
    Haertlein, BJ
    Hecker, LR
    Hecker, LR
    Hulshizer, BL
    Kauffman, JA
    Keane, P
    McComsey, DF
    Mitchell, JA
    Scott, L
    Shah, RD
    Yabut, SC
    Johnson, RW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U32 - U32
  • [20] Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308
    Hoekstra, WJ
    Maryanoff, BE
    Damiano, BP
    Andrade-Gordon, P
    Cohen, JH
    Costanzo, MJ
    Haertlein, BJ
    Hecker, LR
    Hulshizer, BL
    Kauffman, JA
    Keane, P
    McComsey, DF
    Mitchell, JA
    Scott, L
    Shah, RD
    Yabut, SC
    JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (25) : 5254 - 5265